BIENERTOVÁ VAŠKŮ, Julie, Josef TOMANDL, Petr BIENERT, Josef CHOVANEC, Zuzana DOSTÁLOVÁ, Anna VAŠKŮ and Dalibor VALÍK. Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors. World Journal of Oncology. 2011, vol. 2, No 5, p. 232-237. ISSN 1920-4531. Available from: https://dx.doi.org/10.4021/wjon385w.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Circulating Levels of Agouti-Related Peptide in Endometrial Cancer Survivors
Authors BIENERTOVÁ VAŠKŮ, Julie (203 Czech Republic, guarantor, belonging to the institution), Josef TOMANDL (203 Czech Republic, belonging to the institution), Petr BIENERT (203 Czech Republic), Josef CHOVANEC (203 Czech Republic, belonging to the institution), Zuzana DOSTÁLOVÁ (203 Czech Republic), Anna VAŠKŮ (203 Czech Republic, belonging to the institution) and Dalibor VALÍK (203 Czech Republic, belonging to the institution).
Edition World Journal of Oncology, 2011, 1920-4531.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Canada
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/11:00054212
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.4021/wjon385w
Keywords in English Agouti-related peptide; Cachexia; Cancer; Cancer survivors
Changed by Changed by: doc. RNDr. Josef Tomandl, Ph.D., učo 47. Changed: 6/6/2012 08:58.
Abstract
Recently, it has been reported that central administration of agouti-related peptide (AgRP) might have protective effect against cachexia development in tumor-bearing mice. In this study, we determined whether the disease-free endometrial cancer survivors present with different plasma AgRP levels than controls and whether there was an association with the duration of the disease- free interval. The total of 53 endometrial cancer survivors was enrolled in the study along with 93 healthy control women of similar age. Fasting blood samples were obtained and AgRP plasma levels determined using ELISA-based methodology. The AgRP plasma levels were signifi cantly higher in the cases than in the controls; AgRP levels were the lowest in obese control women; on the contrary, the AgRP plasma levels were highest in non-obese cancer survivors. Moreover, we observed signifi cant differences in AgRP levels between the endometrial cancer survivors and the control subjects [p (for comparison of the cases and the controls) = 0.002]. In the regression modeling, AgRP was signifi cantly associated with the BMI as well as the case-control status, and the case-control differences in AgRP levels retained their statistical signifi cance also after adjustment for BMI. Disease-free endometrial cancer survivors who did not develop cachexia during their treatment as well as post-treatment period present with signifi cantly higher AgRP levels than the control population, independently on their BMI and menopausal status which could be indicative of the protective effect of circulating AgRP against cachexia development in endometrial cancer.
PrintDisplayed: 7/8/2024 18:53